523 related articles for article (PubMed ID: 31395078)
1. Colorectal cancer cell-derived CCL20 recruits regulatory T cells to promote chemoresistance via FOXO1/CEBPB/NF-κB signaling.
Wang D; Yang L; Yu W; Wu Q; Lian J; Li F; Liu S; Li A; He Z; Liu J; Sun Z; Yuan W; Zhang Y
J Immunother Cancer; 2019 Aug; 7(1):215. PubMed ID: 31395078
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of the NF-κB pathway by nafamostat mesilate suppresses colorectal cancer growth and metastasis.
Lu YX; Ju HQ; Wang F; Chen LZ; Wu QN; Sheng H; Mo HY; Pan ZZ; Xie D; Kang TB; Chen G; Yun JP; Zeng ZL; Xu RH
Cancer Lett; 2016 Sep; 380(1):87-97. PubMed ID: 27322737
[TBL] [Abstract][Full Text] [Related]
3. Aspirin suppresses chemoresistance and enhances antitumor activity of 5-Fu in 5-Fu-resistant colorectal cancer by abolishing 5-Fu-induced NF-κB activation.
Fu J; Xu Y; Yang Y; Liu Y; Ma L; Zhang Y
Sci Rep; 2019 Nov; 9(1):16937. PubMed ID: 31729451
[TBL] [Abstract][Full Text] [Related]
4. Enalapril overcomes chemoresistance and potentiates antitumor efficacy of 5-FU in colorectal cancer by suppressing proliferation, angiogenesis, and NF-κB/STAT3-regulated proteins.
Yang Y; Ma L; Xu Y; Liu Y; Li W; Cai J; Zhang Y
Cell Death Dis; 2020 Jun; 11(6):477. PubMed ID: 32581212
[TBL] [Abstract][Full Text] [Related]
5. Effect of preoperative FOLFOX chemotherapy on CCL20/CCR6 expression in colorectal liver metastases.
Rubie C; Frick VO; Ghadjar P; Wagner M; Justinger C; Graeber S; Sperling J; Kollmar O; Schilling MK
World J Gastroenterol; 2011 Jul; 17(26):3109-16. PubMed ID: 21912453
[TBL] [Abstract][Full Text] [Related]
6. FoxO3 reverses 5-fluorouracil resistance in human colorectal cancer cells by inhibiting the Nrf2/TR1 signaling pathway.
Liu C; Zhao Y; Wang J; Yang Y; Zhang Y; Qu X; Peng S; Yao Z; Zhao S; He B; Mi Q; Zhu Y; Liu X; Zou J; Zhang X; Du Q
Cancer Lett; 2020 Feb; 470():29-42. PubMed ID: 31811910
[TBL] [Abstract][Full Text] [Related]
7. Fusobacterium nucleatum promotes chemoresistance to 5-fluorouracil by upregulation of BIRC3 expression in colorectal cancer.
Zhang S; Yang Y; Weng W; Guo B; Cai G; Ma Y; Cai S
J Exp Clin Cancer Res; 2019 Jan; 38(1):14. PubMed ID: 30630498
[TBL] [Abstract][Full Text] [Related]
8. CCL20 and CXCL8 synergize to promote progression and poor survival outcome in patients with colorectal cancer by collaborative induction of the epithelial-mesenchymal transition.
Cheng XS; Li YF; Tan J; Sun B; Xiao YC; Fang XB; Zhang XF; Li Q; Dong JH; Li M; Qian HH; Yin ZF; Yang ZB
Cancer Lett; 2014 Jun; 348(1-2):77-87. PubMed ID: 24657657
[TBL] [Abstract][Full Text] [Related]
9. Molecular implications of MUC5AC-CD44 axis in colorectal cancer progression and chemoresistance.
Pothuraju R; Rachagani S; Krishn SR; Chaudhary S; Nimmakayala RK; Siddiqui JA; Ganguly K; Lakshmanan I; Cox JL; Mallya K; Kaur S; Batra SK
Mol Cancer; 2020 Feb; 19(1):37. PubMed ID: 32098629
[TBL] [Abstract][Full Text] [Related]
10. Ursolic acid inhibits growth and metastasis of human colorectal cancer in an orthotopic nude mouse model by targeting multiple cell signaling pathways: chemosensitization with capecitabine.
Prasad S; Yadav VR; Sung B; Reuter S; Kannappan R; Deorukhkar A; Diagaradjane P; Wei C; Baladandayuthapani V; Krishnan S; Guha S; Aggarwal BB
Clin Cancer Res; 2012 Sep; 18(18):4942-53. PubMed ID: 22832932
[TBL] [Abstract][Full Text] [Related]
11. Icariin-mediated inhibition of NF-κB activity enhances the in vitro and in vivo antitumour effect of 5-fluorouracil in colorectal cancer.
Shi DB; Li XX; Zheng HT; Li DW; Cai GX; Peng JJ; Gu WL; Guan ZQ; Xu Y; Cai SJ
Cell Biochem Biophys; 2014 Jul; 69(3):523-30. PubMed ID: 24435883
[TBL] [Abstract][Full Text] [Related]
12. S-Adenosylmethionine Increases the Sensitivity of Human Colorectal Cancer Cells to 5-Fluorouracil by Inhibiting P-Glycoprotein Expression and NF-κB Activation.
Mosca L; Pagano M; Borzacchiello L; Mele L; Russo A; Russo G; Cacciapuoti G; Porcelli M
Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502219
[TBL] [Abstract][Full Text] [Related]
13. FOXM1 evokes 5-fluorouracil resistance in colorectal cancer depending on ABCC10.
Xie T; Geng J; Wang Y; Wang L; Huang M; Chen J; Zhang K; Xue L; Liu X; Mao X; Chen Y; Wang Q; Dai T; Ren L; Yu H; Wang R; Chen L; Chen C; Chu X
Oncotarget; 2017 Jan; 8(5):8574-8589. PubMed ID: 28051999
[TBL] [Abstract][Full Text] [Related]
14. Ginsenoside Rg3 inhibits colorectal tumor growth via down-regulation of C/EBPβ/NF-κB signaling.
Yang X; Zou J; Cai H; Huang X; Yang X; Guo D; Cao Y
Biomed Pharmacother; 2017 Dec; 96():1240-1245. PubMed ID: 29169725
[TBL] [Abstract][Full Text] [Related]
15. Nuclear orphan receptor NR4A2 confers chemoresistance and predicts unfavorable prognosis of colorectal carcinoma patients who received postoperative chemotherapy.
Han Y; Cai H; Ma L; Ding Y; Tan X; Liu Y; Su T; Yu Y; Chang W; Zhang H; Fu C; Cao G
Eur J Cancer; 2013 Nov; 49(16):3420-30. PubMed ID: 23809767
[TBL] [Abstract][Full Text] [Related]
16. 4-Acetylantroquinonol B inhibits colorectal cancer tumorigenesis and suppresses cancer stem-like phenotype.
Chang TC; Yeh CT; Adebayo BO; Lin YC; Deng L; Rao YK; Huang CC; Lee WH; Wu AT; Hsiao M; Wu CH; Wang LS; Tzeng YM
Toxicol Appl Pharmacol; 2015 Oct; 288(2):258-68. PubMed ID: 26235807
[TBL] [Abstract][Full Text] [Related]
17. NF-κB-Mediated CCL20 Reigns Dominantly in CXCR2-Driven Ovarian Cancer Progression.
Ignacio RM; Kabir SM; Lee ES; Adunyah SE; Son DS
PLoS One; 2016; 11(10):e0164189. PubMed ID: 27723802
[TBL] [Abstract][Full Text] [Related]
18. Resveratrol Chemosensitizes TNF-β-Induced Survival of 5-FU-Treated Colorectal Cancer Cells.
Buhrmann C; Yazdi M; Popper B; Shayan P; Goel A; Aggarwal BB; Shakibaei M
Nutrients; 2018 Jul; 10(7):. PubMed ID: 30002278
[No Abstract] [Full Text] [Related]
19. MicroRNA-149 Increases the Sensitivity of Colorectal Cancer Cells to 5-Fluorouracil by Targeting Forkhead Box Transcription Factor FOXM1.
Liu X; Xie T; Mao X; Xue L; Chu X; Chen L
Cell Physiol Biochem; 2016; 39(2):617-29. PubMed ID: 27415661
[TBL] [Abstract][Full Text] [Related]
20. miR-193a-5p as a promising therapeutic candidate in colorectal cancer by reducing 5-FU and Oxaliplatin chemoresistance by targeting CXCR4.
Azar MRMH; Aghazadeh H; Mohammed HN; Sara MRS; Hosseini A; Shomali N; Tamjidifar R; Tarzi S; Mansouri M; Sarand SP; Marofi F; Akbari M; Xu H; Shotorbani SS
Int Immunopharmacol; 2021 Mar; 92():107355. PubMed ID: 33429333
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
